Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Stonegate working on a research report?

<< Previous

Bullboard Posts

Next >>

Comment by tylerreddickon May 11, 2024 8:35am

100 Views

Post# 36035079

RE:RE:Stonegate working on a research report?

Turtle4 wrote: Such paid reports are pointless. Nobody believes them and they only serve the CEO's ego so that he can proudly post this report on Twitter. Every serious investor does his own research.

Normally I would agree with you.
But if Stonegate is doing an evaluation to present to an institution (fund) that is considering supporting Sirona Labs, that investor will not accept a bs report.

As far as us little guys doing our own research, I doubt many here have the knowhow to figure out what a skin care product might be worth. Do you?

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario